SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-014649
Filing Date
2021-03-11
Accepted
2021-03-10 17:33:51
Documents
4
Period of Report
2021-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea137374-8k_inmunebioinc.htm 8-K 25638
2 AT-THE-MARKET SALES AGREEMENT, DATED MARCH 10, 2021, BETWEEN THE COMPANY AND BTI ea137374ex1-1_inmunebioinc.htm EX-1.1 282819
3 OPINION OF SICHENZIA ROSS FERENCE LLP ea137374ex5-1_inmunebioinc.htm EX-5.1 13573
4 GRAPHIC ex5-1_001.jpg GRAPHIC 5806
  Complete submission text file 0001213900-21-014649.txt   331312
Mailing Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037
Business Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

IRS No.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 21730995
SIC: 2836 Biological Products, (No Diagnostic Substances)